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Losartan potassium is an antihypertensive non­peptide agent, which exerts its action by specific blockade 
of angiotensin II receptors. The aim of the present study was the validation and application of analytical 
methods for the quality control of losartan potassium 50 mg in pharmaceutical capsules, using direct and 
first­derivative UV spectrophotometry. Based on losartan potassium spectrophotometric characteristics, a 
signal at 205 nm of the zero­order spectrum and a signal at 234 nm of the first­derivative spectrum, were 
found adequate for quantification. The results were used to compare these instrumental techniques. The 
linearity between the signals and concentrations of losartan potassium in the ranges of 3.0­7.0 mg L­1 
and 6.0­14.0 mg L­1 for direct and first­derivative spectrophotometry in aqueous solutions, respectively, 
presented a correlation coefficient (r) of 0.9999 in both cases. The methods were applied for losartan 
potassium in capsule dosage obtained from local pharmacies, and were shown to be efficient, easy to apply 
and low cost. These methods do not use polluting reagents and require relatively inexpensive equipment. 
Uniterms: Losartan potassium. Direct UV spectrophotometry. First­derivative UV spectrophotometry.
O losartano potássico é um agente anti­hipertensivo não peptídico, que exerce sua ação por bloqueio 
específico dos receptores da angiotensina II. Este trabalho propôs a validação e aplicação de métodos 
analíticos orientados ao controle de qualidade de losartano potássico 50 mg na forma farmacêutica 
cápsula, utilizando a espectrofotometria direta e derivada de primeira ordem na região do UV. Baseado nas 
características espectrofotométricas de losartano potássico, um sinal a 205 nm do espectro de ordem zero e um 
sinal a 234 nm do espectro de primeira derivada foram adequados para a quantificação. Os resultados foram 
usados para comparar essas duas técnicas instrumentais. O coeficiente de correlação entre as respostas e as 
concentrações de losartano potássico na faixa de 3,0­7,0 mg L­1 e 6,0­14,0 mg L­1 para espectrofotometria 
direta e derivada de primeira ordem em solução aquosa, respectivamente, foi de (r) of 0,9999 para ambos 
os casos. Os métodos foram aplicados para quantificação de losartano potássico em cápsulas obtidas de 
farmácias de manipulação locais e demonstraram ser eficientes, fáceis de aplicar e de baixo custo. Além 
disso, não necessitam de reagentes poluentes e requerem equipamentos economicamente viáveis.
Unitermos: Losartano potássico. Espectrofotometria direta. Espectrofotometria derivada de primeira 
ordem.
INTRODUCTION
Losartan potassium (Figure 1) is an imidazole 
derivative, chemically described as 2­butyl­4­chloro­
1­[p-(o-1H-tetrazol­5­ylphenyl)benzyl]imidazole­5­
methanol monopotassium salt. Losartan was developed 
by DuPont­Merck laboratories as a potent non­peptide 
angiotensin II receptor (type AT
1
) antagonist for hyper­
tension treatment (Barreiro, Fraga, 2001; Korolkovas, 
2007). Losartan is administered in its active form and 
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is partially converted into an active metabolite which is 
responsible for the drug’s prolonged pharmacological 
effect. The therapeutic efficacy of losartan, as well as its 
renal and antihypertensive effects, seems to be similar to 
those of angiotensin converting enzyme (ACE) inhibi­
tors. However, its adverse effects are different, mainly 
regarding coughing, whose incidence is significantly 
lower compared with ACE inhibitors (Oigman, 1996). 
Losartan potassium is a light yellow solid with a mo­
lecular weight of 461; melting point of 183.5­184.5 ºC; 
aqueous solubility of 3.3 mg mL­1 at pH 7.8 and pKa 
value of 4.9 (Lastra et al., 2003; Williams et al., 1996).
The literature has described several analytical 
methods for losartan potassium determination in tablets, 
when used as a single active principle or in combination 
with hydrochlorothiazide, using high performance liquid 
chromatography (HPLC), capillary electrophoresis, super­
critical fluid chromatography, high performance thin layer 
chromatography and derivative ultraviolet spectrophotom­
etry (Ansari et al., 2004; Erk, 2001; Lastra et al., 2003; 
Mccarthy et al., 1998; Williams et al., 1996). For losartan 
potassium determination in pharmaceutical capsules, two 
HPLC methods have been reported (Bonfilio et al., 2009; 
Maio, Dias, Bergold, 2005).
However, to date, no analytical method has been 
described in the literature that uses direct or first­derivative 
spectrophotometry for quantitative analysis of losartan 
potassium in pharmaceutical capsules, which is fre­
quently formulated in magistral pharmacies. Moreover, 
no pharmacopoeia have yet described a monograph for 
the finished product.
The aim of the present study was to investigate the 
validation and application of analytical methods for qual­
ity control of 50 mg losartan potassium pharmaceutical 
capsules, using both direct and fi rst­derivative UV spec­
trophotometry.
MATERIALS AND METHODS
Pharmaceutical products, chemical reference 
substance and solvent
Pharmaceutical capsules containing 50 mg of losa­
rtan potassium were kindly provided by three magistral 
pharmacies localized in the region of Alfenas, Minas 
Gerais state, Brazil, and were coded as products A, B and 
C. The capsules had a four­month validity period (�anu­
ary 26th, 2008; December 6th, 2007 and �une 12th, 2007, 
respectively). The capsules were described as containing 
the following pharmaceutical grade excipients: magne­
sium stearate (All­Chemistry and YOD, Brazil); aerosol 
(All­Chemistry and Ely Martins, Brazil); sodium dodecyl 
sulphate (All­Chemistry e Gerbrás, Brazil); talc (DEG, 
Labsynth and Pharma Nostra, Brazil); starch (DEG, Bra­
zil) and microcel MC­102 1 (DEG, Brazil). 
 Losartan potassium salt of 98.90� purity sup­
plied by IPCA Laboratories Limited (Athal, India), lot 
5069LB2RI and expiration date of 2009/09 was used as 
the chemical reference substance. Distilled water was used 
as the solvent.
Equipment
The following equipment was used: Shimadzu UV­
1601 (Kyoto, �apan) recording double beam UV–visible 
spectrophotometer connected to a computer running 
Shimadzu UVPC version 3.9 software; ultrasonic bath 
model USC2800A (Unique, São Paulo, Brazil); analytical 
balance model 410 (Kern, Kern, Germany); pHmeter PA 
200 (Marconi S.A., Piracicaba, Brazil); water distiller 
system model 425 (Nova Técnica, Piracicaba, Brazil) and 
quantitative filter paper (Vetec, Rio de �aneiro, Brazil).
Losartan potassium stock standard solution
Stock standard solution of losartan potassium was 
prepared by accurately weighing 25.0 mg of losartan potas­
sium reference substance into a 50 mL volumetric flask and 
adding 40 mL of distilled water. The flask was sonicated for 
10 min, filled to volume with distilled water, and the solution 
was then filtered through quantitative filter paper. 
Capsule solution
From the average weight obtained of 20 capsules of 
each product (by subtracting the weight of the shell from 
the weight of the full 20 capsules), a weight equivalent to 
25.0 mg of losartan potassium was accurately transferred 
FIGURE 1 - Losartan potassium chemical structure.
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into a 50 mL volumetric flask to which 40 mL of distilled 
water was added. The flasks were coded as A, B and C, 
sonicated for 10 min and filled to volume with distilled 
water. Subsequently, the solutions were filtered through 
quantitative filter paper. 
Spectrophotometric measurements
Zero­order spectra were obtained in the UV range 
300­200 nm with a fixed slit width of 2 nm, scan speed of 
about 3200 nm min­1 and 0.2 nm data interval. The first­
derivative spectra were obtained through instrumental 
electronic differentiation (UVPC version 3.9 software) us­
ing a delta lambda of 8 nm. The amplitude values, obtained 
in the first­derivative spectra, were arbitrary units of the 
distance from the central zero base line to the signal ob­
tained at 234 nm. The spectrophotometric measurements 
were recorded using distilled water as a blank solution. 
Method validation (Barros, Hirata, 2002; Brasil, 
2003; F. Bras., 1988; ICH, 1995; INMETRO, 2000; 
Ribani, 2004; USP, 2007).
Selectivity
Selectivity was evaluated by zero­order and the first­
derivative absorption spectra analyses at 5.0 mg L­1 and 10 
mg L­1, respectively, in the range 300­200 nm using losar­
tan potassium and pharmaceutical capsule products A, B 
and C solutions. This procedure was also carried out using 
three excipient mixtures containing the same quantitative 
composition as the pharmaceutical products A, B and C.
Linearity
For the linearity study, the losartan potassium stock 
solution was diluted as appropriate with distilled water to 
obtain final losartan potassium concentrations of 3.0, 4.0, 
5.0, 6.0 and 7.0 mg L­1 in five replicates. The analytical curve 
was produced by plotting drug concentration versus the ab­
sorbance values at 205 nm. A second analytical curve for the 
final concentrations of 6.0, 8.0, 10.0, 12.0 and 14.0 mg L­1 was 
constructed by plotting drug concentration versus amplitude 
values of the first­derivative spectra at 234 nm.
Precision
Precision was evaluated with respect to both re­
peatability and intermediate precision. Repeatability 
was evaluated by analyzing six losartan potassium work 
standard solution replicates using distilled water as the 
solvent. The solutions were analyzed using both direct 
and first­derivative UV spectrophotometry at 5.0 mg L­1 
and 10.0 mg L­1, respectively. This procedure was repeated 
over a short period of time on the same day. 
Intermediate precision was also evaluated by analyz­
ing six independent losartan potassium solutions, where 
this procedure was repeated on different days by different 
analysts. The R.S.D values for determinations were also 
calculated.
Accuracy
Accuracy was determined by recovery of known 
amounts of losartan potassium work standard added to 
the pharmaceutical capsule products A, B and C. In the 
direct spectrophotometric method, products A, B and C 
sample solutions were prepared in triplicate at a losartan 
potassium concentration of 2.5 mg L­1. Adequate standard 
solution volumes were added to the sample solutions to 
obtain final concentrations of 4.0, 5.0 and 6.0 mg L­1. In 
the first­derivative spectrophotometric method, products 
A, B and C sample solutions were prepared in triplicate at 
a concentration of 5.0 mg L­1. Adequate standard solution 
volumes were added to the sample solutions to obtain final 
concentrations of 8.0, 10.0, and 12.0 mg L­1. The resulting 
mixtures were analyzed by the proposed methods and the 
percentage recoveries were calculated.
Robustness
In order to verify the method’s resilience to slight and 
deliberate variations in the analytical parameters, losartan 
potassium solutions at 5.0 and 10.0 mg L­1 were analyzed by 
direct and first­derivative UV spectrophotometric methods, 
respectively. The robustness was assessed by comparison 
of the results obtained under standard conditions against 
those obtained using different cuvettes and at different room 
temperatures (Turning off the air conditioner). 
Detection and quantitation limits
The detection (DL) and quantitation (QL) limits of 
the spectrophotometric methods were calculated using 
Equations (1) and (2): 
  DL = 3(S.D/a) (1)
  QL= 10(S.D/a) (2)
where S.D. is the 20 spectrophotometric blank reading 
(distilled water) standard deviation and a is the calibration 
curve slope obtained in the linearity study.
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Aqueous stability
The losartan potassium stock solution was diluted to 
concentrations of 5.0 and 10.0 mg L­1 using distilled water 
and analyzed by direct and fi rst­derivative UV spectropho­
tometry, respectively. The analyses were carried out in the 
periods of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 12 and 24 hours after 
solution preparation.
Average weight determination
In order to determine the mean weight of pharma­
ceutical capsule products A, B and C, 20 capsules were 
weighed and then capsule content removed. The empty 
shells were weighed, and the content average weight 
obtained by subtracting the weight of the shell from the 
weight of the full 20 capsules, as recommended by the 
Brazilian Pharmacopoeia (F. Bras., 1988). The R.S.D 
values for determinations were then calculated.
Pharmaceutical capsule assay
The validated analytical methods were applied to 
determine losartan potassium content for the pharmaceuti­
cal capsule products A, B and C using both direct and first­
derivative UV spectrophotometric methods at 5.0 mg L­1 
and 10.0 mg L­1, respectively. The results were obtained 
by comparing the sample spectrophotometric measure­
ments (n=5) with those obtained from losartan potassium 
standard solutions (n=3) at the same concentration levels. 
Content uniformity determination
The content of ten capsules of each product was 
individually transferred to 100 mL volumetric flasks 
and 40 mL of distilled water was added. The flasks were 
sonicated for 10 min and filled to volume with distilled 
water. The solution was filtered with quantitative filter 
paper, diluted to concentrations of 5.0 and 10.0 mg L­1 and 
analyzed by direct and first­derivative UV spectrophoto­
metric methods, respectively, by comparing the sample 
spectrophotometric measurements with those obtained 
from losartan potassium standard solutions (n=3) at the 
same concentration levels. 
RESULTS AND DISCUSSION
Lastra and coworkers studied losartan potassium 
solution spectrophotometric behavior at various pH values 
and concluded that a pH variation from 5 to 9 did not alter 
losartan potassium spectral characteristics (Lastra et al., 
2003). Distillation is the most common process used in 
magistral pharmacies for preparing the purified water to be 
used in the drug­manipulation and quality control activi­
ties, and the recommended pH of distilled water is between 
5.0 and 7.0 (USP, 2007). The use of water as a solvent in 
chemical analysis laboratories has many advantages in 
terms of environmental aspects, cost and safety compared 
with the use of an organic solvent. Therefore, considering 
the losartan potassium aqueous solubility of 3.3 mg mL­1 
(Lastra et al., 2003; Williams et al., 1996) and the factors 
mentioned above, the use of distilled water as solvent was 
deemed adequate for our validation purposes, making the 
methods simple and convenient.
The zero­order spectrum of losartan potassium so­
lution at 5.0 mg L­1 in distilled water showed maximum 
drug absorption wavelength at 205 nm with absorbance 
values of 0.5 (Figure 2). Therefore, the absorbance values 
at 205 nm were used in the direct spectrophotometric me­
thod while 5.0 mg L­1 was fixed as the 100 percent level 
on the analytical curve.
Previously published studies justified the use of 
first­derivative spectrophotometry for losartan potassium 
determination in tablets by stating that the maximum 
drug absorption wavelength is close to 205 nm and that 
no absorption peak is observed at other wavelengths 
(Lastra et al., 2003). Moreover, the interference from the 
tablet excipients verified at close to 205 nm, precludes the 
analytical use of zero­order spectrophotometry for losartan 
potassium determination in tablets (Ansari et al., 2004).
The absorption spectrum differentiation through de­
rivative spectrophotometry does not increase the original 
spectrum information, but derivative operation reduces the 
broad band intensity, yielding overlapping peak resolution 
enhancements, obeying Beer’s law (Paschoal et al., 2003). 
FIGURE 2 – Losartan potassium zero­order absorption spectrum 
at 5 mg L­1 using distilled water as solvent.
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The first­derivative spectrum, obtained through instru­
mental electronic differentiation of the losartan potassium 
zero­order absorption spectrum, shows an intense negative 
peak at 234 nm (Figure 3). At this wavelength, a losartan 
potassium solution of 5.0 mg L­1 shows absorbance values 
of 0.25. For the subsequent analyses, 10.0 mg L­1 was fixed 
at the 100 percent level of the analytical curve in the first­
derivative spectrophotometric method in order to produce 
a analytical signal that corresponded to those observed 
under the direct spectrophotometric method.
In these experiments, formulation excipients of 
capsules A, B and C did not present absorbance at 205 nm, 
demonstrating the direct spectrophotometric method se­
lectivity for losartan potassium analysis in pharmaceutical 
capsules (Figure 4). Use of direct spectrophotometry is 
advantageous because it can be used by analytical labo­
ratories that do not have access to a spectrophotometer 
with derivative mode. However, direct spectrophotometric 
method selectivity was confirmed using only the following 
excipients: magnesium stearate, aerosil, sodium dodecyl 
sulfate, talc, starch and microcel MC­102 1. Because 
there is a considerable variety in the excipients used in 
the drug­manipulation process, the direct spectrophoto­
metric method selectivity should be further verified for 
pharmaceutical capsules containing different excipients 
than those tested in this study, which could be considered 
a drawback of this method.
The first­derivative spectra analyses showed that 
capsule A, B and C formulation excipients did not inter­
fere in the first­derivative spectrophotometric method 
(Figure 5).
Although the spectrophotometric methods are not 
effective for identifying or quantifying impurities and 
degradation products, the drug substance used in the 
losartan potassium capsule manipulation should have been 
adequately analyzed and an analysis certificate should 
issued by the supplier guaranteeing compliance with the 
acceptance criteria in accordance with the drug substance 
monograph on losartan potassium provided by the United 
States Pharmacopoeia, which establishes a 0.2� limit for 
any individual impurity and no more than 0.5� of total 
impurities (USP, 2007).
The linearity results were evaluated by linear 
regression analysis based on the minimum­square 
method. The correlation coefficient value obtained from 
direct spectrophotometric method over the range 3.0 to 
7.0 mg L­1 was r=0.9999 and the calibration equation was: 
A = 0.095C – 0.0048. From the first­derivative spectropho­
tometry, the correlation coefficient value obtained over the 
range 6.0 to 14.0 mg L­1 was r=0.9999 and the calibration 
equation was dA/dl=­0.0022C – 0.0004. In both cases, the 
FIGURE 3 – Losartan potassium first­order absorption spectrum 
at 5 mg L­1 using distilled water as solvent.
FIGURE 4 – Zero­order absorption spectra of standard losartan 
potassium aqueous solution at 5 mg L­1, capsule products A, B 
and C at 5 mg L­1 and A, B and C product excipients.
FIGURE 5 – First­derivative absorption spectra of standard 
losartan potassium aqueous solution at 10 mg L­1, capsule 
products A, B and C at 10 mg L­1 and A, B and C product 
excipients.
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relative standard deviation of each point (n=5) was lower 
than 2�. The results show linear correlation between 
analytical responses and drug concentration.
Overall relative standard deviations for repeatability 
and intermediate precision were 0.95 � and 0.75 � using 
direct spectrophotometry. In the case of first­derivative 
spectrophotometry, the overall relative standard deviations 
for repeatability and intermediate precision were 0.95 � 
and 0.75 �. These experimental results confirmed good 
precision of the methods when performed on the same or 
different days by different analysts. Relative standard de­
viations lower than 5� are considered acceptable (Brasil, 
2003). 
The spectrophotometric analytical methods showed 
good accuracy, evaluated by the recovery test (Tables I and 
II). The mean recovery percentages of 99.00, 101.74 and 
98.91 for products A, B and C, respectively, using direct 
spectrophotometry, and 101.19, 99.86 and 101.56 � for 
products A, B and C using first­derivative spectrophotome­
try, corroborated satisfactory recovery. Recovery values 
from 98.0 to 102.0 � are deemed acceptable.
The robustness test examines the experimental 
conditions for the method, and the potentially responsible 
factors such as experimental and environmental condi­
tions, to be taken into account during method development 
given that changes in the optimal conditions can result in 
significant errors. For both analytical methods, the low 
RSD values demonstrated that the analysis factors (cuvette 
and room temperature) did not have a significant effect on 
analytical responses (Tables I and II).
The direct spectrophotometry detection and quan­
titation limits were found to be 0.01 and 0.04 mg L­1, 
respectively, whereas detection and quantitation limits for 
first­derivative spectrophotometry were found to be 0.07 
and 0.23 mg. L­1, respectively. These results demonstrated 
that the analyses were being performed in a region above 
the quantitation limit value.
Aqueous stability of losartan potassium was checked 
by evaluation of direct and first­derivative spectra at regu­
lar time intervals up to 24 hours, and yielded no significant 
alteration in spectral characteristics (Figures 6 and 7).
The average weights of pharmaceutical capsule 
products A, B and C were 132.33 mg, 155.12 mg and 
158.02 mg, respectively. All products showed acceptable 
weight values as stipulated by the Brazilian Pharmaco­
poeia, which establishes that capsules of ≤ 300 mg may 
not deviate by more than 10.0 � w/w from the average 
weight (F. Bras., 1988).
TABLE I – Direct spectrophotometry validation values for losartan potassium evaluation in capsules
Parameter Condition Concentration level
(mg L­1)
Absorbance mean 
Values 
R. S. D.
(�)
Mean recovery
(�)
Precision
Repeatability
Intermediate 
Series 1
Series 2
Day 1
Day 2
5.0
5.0
5.0
5.0
0.482
0.482
0.490
0.487
0.79 (n=6)
1.11 (n=6)
0.70 (n=6)
0.79 (n=6)
Accuracy Sample A
Sample B
Sample C
4.0
5.0
6.0
4.0
5.0
6.0
4.0
5.0
6.0
0.377
0.477
0.570
0.372
0.466
0.563
0.396
0.498
0.596
0.55 (n=3)
0.36 (n=3)
0.62 (n=3)
0.82 (n=3)
0.33 (n=3)
0.00 (n=3)
0.39 (n=3)
0.83 (n=3)
0.86 (n=3)
99.00
101.74
98.91
Robustness Cuvette 1
Cuvette 2
Air conditioner 
turned off
5.0
5.0
5.0
0.599
0.599
0.600
0.12 (n=3)
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FIGURE 6 – Aqueous stability evaluation of 5.0 mg L­1 losartan 
potassium aqueous solutions using zero­order spectra at regular 
time intervals up to 24 hours.
FIGURE 7 – Aqueous stability evaluation of 10.0 mg L­1 losartan 
potassium aqueous solutions using first­derivative absorption 
spectra at regular time intervals up to 24 hours.
TABLE II – First­derivative spectrophotometry validation values for losartan potassium evaluation in capsules
Parameter Condition Concentration level
(mg L­1)
Response Mean Values 
(dA/dl)
R. S. D.
(�)
Mean recovery
(�)
Precision
Repeatability
Intermediate 
Series 1
Series 2
Day 1
Day 2
10.0
10.0
10.0
10.0
­0.0204
­0.0208
­0.0219
­0.0203
0.92 (n=6)
0.86 (n=6)
0.53 (n=6)
0.99 (n=6)
Accuracy Sample A
Sample B
Sample C
8.0
10.0
12.0
8.0
10.0
12.0
8.0
10.0
12.0
­0.0148
­0.0188
­0.0225
­0.0159
­0.0200
­0.0237
­0.0163
­0.0202
­0.0241
0.39 (n=3)
0.31 (n=3)
0.26 (n=3)
0.00 (n=3)
0.50 (n=3)
0.24 (n=3)
0.71 (n=3)
0.00 (n=3)
0.24 (n=3)
101.19
99.86
101.56
Robustness Cuvette 1
Cuvette 2
Air conditioner 
turned off
10.0
10.0
10.0
­0.0221
­0.0222
­0.0221
0.21 (n=3)
The methods were applied to losartan potassium 
pharmaceutical capsule products A, B and C , and the 
drug percentage values related to label claim are shown in 
Table III. The results show that the drugs assayed were in 
accordance with Brazilian Pharmacopoeia, which estab­
lishes limits between 90 and 110 � of the labeled amount 
for finished products (F. Bras., 1988).
The content uniformity test showed that individual 
active content values and relative standard deviations of 
pharmaceutical capsule products A and C (n=10) were 
acceptable and met the requirements. Individual values 
of active content for sample B were found to lie in the 
range of 85–115�; however the relative standard deviation 
observed was higher than 6 � (Table III). The individual 
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results should lie between 85 and 115 � of label claim, 
with a R. S. D. < 6.0 � (F. Bras., 1988).
The proposed analytical methods were compared 
using individual active content values obtained from the 
content uniformity test. The statistical analysis was carried 
out using a 10×3×2 factorial design (ten active content val­
ues, three products and two methods). Data were submitted 
to analysis of variance followed by Tukey’s test at a 0.05 
significance level. The parameters of pharmaceutical cap­
sule products (A, B and C) and analytical methods (direct 
and first­derivative spectrophotometry) were compared. 
The results showed no significant active content values 
differences among products A, B and C, or between direct 
and first­derivative spectrophotometric methods (p>0.05).
CONCLUSIONS 
Both direct and first­derivative spectrophotometric 
methods were shown to be efficient, low cost and easy to 
apply for losartan potassium determination in pharma­
ceutical capsules. They do not use polluting reagents and 
require relatively inexpensive equipment. 
All validation parameters were found to be highly 
satisfactory, indicating linearity, selectivity, precision, 
accuracy, robustness and adequate detection and quan­
tification limits of both direct and first­derivative spec­
trophotometric methods. The methods were therefore 
shown to be suitable for losartan potassium evaluation 
of pharmaceutical capsules and for routine use in quality 
control laboratories.
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Losartan (�) 98.06 99.18 96.08 94.54 99.25 99.61
R. S. D. (�) 1.10 (n=5) 0.78 (n=5) 1.93 (n=5) 1.16 (n=5) 1.00 (n=5) 0.61 (n=5)
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Comparative study of analytical methods by direct and first­derivative UV spectrophotometry 155
FARMACOPÉIA Brasileira. 4.ed. São Paulo: Atheneu, 1988. 
v.1,v.2, p. v.1.1, v.2.14, v.1.6.
ICH. International Conference on Harmonization. Validation 
of Analytical Procedures: Methodology, Q2B (CPMP/
ICH281/95), 1995. Available at:<http://www.fda.gov/cder>. 
Accessed on: 15 jan.2008.
INMETRO. Guia para laboratórios químicos: um auxílio 
à organização e ao credenciamento. Rio de �aneiro: 
Interciência, 2000. p.41.
KOROLKOVAS, A. Dicionário terapêutico Guanabara. Ed. 
2006/2007. Rio de �aneiro: Guanabara Koogan, 2007. 
p.8­33. 
LASTRA, O. C.; LEMUS, I. G.; SÁNCHEZ H. �.; PÉREZ, 
F. Development and validation of an UV derivative 
spectrophotometric determination of losartan potassium in 
tablets. J. Pharm. Biomed. Anal., v.33, n.2, p.175­180, 2003.
MAIO, V.; M DOS, P.; DIAS, C. L.; BERGOLD, A. M. 
Validation of an isocratic HPLC assay of losartan potassium 
in pharmaceutical formulations and stress test for stability 
evaluation of drug substance. Acta Farm. Bonaerense, v.24, 
n.2, p.250­255, 2005.
MCCARTHY, K. E.; WANG, Q.; TSAI, E. W.; DOMINIC, 
P. I.; BROOKS, M. A. J. Determination of losartan and 
its degradates in COZAAR® tablets by reversed­phase 
high­performance thin­layer chromatography. J. Pharm. 
Biomed.. Anal., v.17, n.4­5, p.671­677, 1998.
OIGMAN, W. Tratamento farmacológico da hipertensão arterial 
essencial. Medicina, Ribeirão Preto, v.29, n.2­3, p.244­249, 
1996. 
PASCHOAL, L. R.; FERREIRA, W. A.; PRADO, M. 
R. D.; VILELA, A. P. O. Aplicação do método da 
espectrofotometria de derivadas na identificação e 
doseamento simultâneo de sistemas multicomponentes. Rev. 
Bras. Cienc. Farm., v.39, n.1, p.105­113, 2003.
RIBANI, M. Validação em métodos cromatográficos e 
eletroforéticos. Quim. Nova, v.27, n.5, p.771­780, 2004.
UNITED STATES PHARMACOPOEIA. 30.ed. Rockville: 
United States Pharmacopoeia Convention, 2007. p.2499­
3050.
WILLIAMS, R. C.; ALASANDRO, M. S.; FASONE, V. L.; 
BOUCHER, R. �.; EDWARDS, �. F.; J. Comparison of 
liquid chromatography, capillary electrophoresis and 
super­critical fluid chromatography in the determination 
of Losartan Potassium drug substance in Cozaar ® tablets. 
J. Pharm. Biomed. Anal., v.14, n.11, p.1539­1546, 1996.
Received for publication on 09th December 2008
Accepted for publication on 27th September 2009

